Clinical Trial Update: Bevacizumab and Radiotherapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver Gene [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating bevacizumab with radiotherapy for oligometastasis in lung adenocarcinoma with negative driver gene mutations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Lung Adenocarcinoma | Phase 2 | Status: UNKNOWN